Omada Health

2mo

Our nutrition experience, powered by OmadaSpark built on Amazon SageMaker AI, is trained on clinical protocols, peer‑reviewed literature, and specialty guidelines so members get safe, context-aware education informed by their conditions and goals in real time with meaningful interactions.So when members need help at the moment - standing in their kitchen or looking at a menu, they’re not alone: OmadaSpark can help them navigate emotional eating and make choices that align with the care plan built with their care team. Learn more about how we built the experience with AWS AI and AI at Meta: https://lnkd.in/di4uSZr6

Omada Health

2mo

GLP‑1 Flex Care gives employers a way to offer their workforce access to anti‑obesity medications—even when traditional coverage isn’t financially feasible. Through established cash‑pay channels, members who independently obtain their prescriptions can access Omada’s wraparound care: from prescription to lifestyle counseling to ongoing clinical oversight, all the way through safe discontinuation. GLP-1 Flex Care will be available to employers later in 2026. Want to learn more about our new offering? https://lnkd.in/eDx3Wj6R

Omada Health

2mo

We're proud to share $OMDA's Q1 2026 results as proof that growth and durability can compound together, even in our most cost-intensive quarter: 📈 Revenue up 42% YoY to $78M 👥 Total Members surpassed 1M for the first time, up 51% YoY 📉 GAAP net loss narrowed to $3M (vs. $9M in Q1 2025) 💫 Positive adjusted EBITDA, even in our historically highest-cost quarter Click in to see how we’re delivering on our four growth levers - these proof points reinforce that Omada is becoming part of the connective tissue between how employers buy, how members engage, and how outcomes are delivered across the digital cardiometabolic landscape. Full Q1 2026 release with GAAP to non-GAAP reconciliation: https://lnkd.in/dF7wPJJB

Omada Health

2mo

Last week, we hosted an esteemed group of consultants in Nashville for our roundtable, GLP‑1s + AI: Powering the Next Era of Cardiometabolic Care. Over two days, thought leaders explored the rapidly evolving AI policy landscape with Ben Moscovitch and examined how AI is transforming cardiometabolic care with insights from Dr. Faraz Ahmad. We also shared Omada’s latest AI-powered innovations, along with real-world GLP‑1 outcomes—including muscle mass preservation and sustained weight management. Thank you to the consultants who joined us, our expert speakers and partners, and the Omada team who brought this program to life. We look forward to continuing the conversation and collaborating to shape the next era of cardiometabolic care.

Omada Health

2mo

Join Horizon Day 2026 for a LinkedIn Live reveal of how Omada is redefining cardiometabolic care as GLP-1s reshape the obesity treatment landscape. Don't miss Omada's Sean Duffy and Wei-Li Shao as they showcase Omada’s integrated approach, including a walk-through of GLP-1 prescribing and the guided medication care experience. They'll also reveal the strategy and vision shaping the future of Omada's care model. We’ll be taking audience Q&A in real time during the event, so join us—and join the conversation.

Omada Health

2mo

For employers, the real GLP‑1 budget question isn’t just “What do they cost?”—it’s “What do we get for our spend?” Omada acts as a GLP‑1 value maximizer. Our GLP‑1 Care Track includes nutrition guidance, human coaching, and behavior‑change support around medication to improve persistence, manage side effects, and support healthy discontinuation so results last. Our research has shown that members in Omada’s GLP‑1 program achieved greater weight loss and better weight maintenance on average than real world evidence. Not all access is created equal - learn more about how to maximize value from the investment in this piece by Wei-Li Shao: https://lnkd.in/dcsC6h7k

Omada Health

2mo

The American Heart Association (AHA) recently released a Presidential Advisory with a stark warning: Healthcare affordability in America has reached a crisis point. We're spending nearly $5T a year on healthcare, and the AHA projects that healthcare costs related to cardiovascular disease will quadruple by 2050. Senior Director of Clinical Affairs, Kevin Masci, Pharm D, explains why virtual chronic condition care between doctor visits is exactly the kind of strategic investment the AHA is calling for. We shouldn’t have to choose between affordability and quality care. The solution is already here. It's time to scale it.

Omada Health

2mo

Flexible benefit design solutions. One place for virtual GLP‑1 care. Together, they’re a win for employers. At a time when GLP-1 usage is surging, Omada’s new GLP-1 Flex Care gives employers a way to support healthy weight loss for their employees without taking on expense. For members who independently purchase GLP-1 medications through established cash-pay channels, Omada can provide wraparound lifestyle support that’s proven to deliver outcomes — all in one place. At one year, outcomes included: 💡 ~2x greater average weight loss for GLP-1 members than real-world evidence with standard care 💡 67% continued GLP-1 usage compared to 47-49% in real-world evidence 💡 63% maintained or continued to lose weight post GLP-1 discontinuation

Omada Health

2mo

Omada Health is now available through OptumRx's Weight Engage program, meaning employers can now purchase Omada through all three largest PBMs. GLP-1s have changed the weight management conversation, but medication alone isn't the answer. Our recent research reinforces why: members pairing GLP-1s with Omada lost more fat and preserved more muscle mass compared to GLP-1 patients not in Omada’s program. The behavior change wrapped around the medication is what helps improve health outcomes. Through their Weight Engage program, OptumRx clients can now offer members Omada's integrated cardiometabolic platform: GLP-1 medication care paired with behavior change program that includes personalized coaching, nutrition and exercise support, side effect management, and community support. Learn more: https://lnkd.in/dGgz-EE6

Omada Health

2mo

The relationship between GLP‑1s, body composition, and movement is more complicated than a simple “miracle drug” or “muscle loss” story. When you look closely at new data from Omada’s Insights Lab alongside emerging research, a different narrative comes into focus: with the right support, people on GLP‑1s are not just losing weight, they’re changing how they move, function, and feel in ways that traditional metrics often miss. In our latest edition of Proof Points, Physical Therapist Todd Norwood, PT, DPT, FACHE and Endocrinologist Rajiv R. unpack what 12 weeks of real-world data tells us about fat vs. muscle loss, why physical function matters as much as the scale, and how to design GLP-1 programs that optimize the quality of weight loss—not just the quantity. Read it here ↓